{'fraction_non_alphanumeric': 0.01794616151545364, 'fraction_numerical': 0.003988035892323031, 'mean_word_length': 5.562091503267974, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The era of ErbB-receptor-targeted therapies: advances toward personalized medicine.

Central themes in medical practice are the diagnosis, prognosis and treatment of disease. Advances have been made in a number of malignanices including breast cancer, where new therapeutic strategies have significantly improved response rates, the disease-free interval and overall survival. However, complete responses to chemotherapy are achieved in only 10-20% of patients. Recent advances in the understanding of the cellular and molecular biology of cancer have led to the identification of oncogenes and tumor suppressor genes that influence the rate of tumor cell proliferation and cancer progression. These oncogenes represent important therapeutic targets and are currently being incorporated into the design of novel therapeutic approaches. This review emphasizes the role of the ErbB oncogenic receptor family, its effect on tumor biologic behavior and its role as a target for various therapeutic regimens.